Department of Gastrointestinal Tumor Surgery, Shenyang Coloproctology Hospital, Shenyang, 110001, China.
Department of Anorectal, Shenyang Coloproctology Hospital, No. 9, Nanjing North Street, Heping District, Shenyang, 110001, China.
Funct Integr Genomics. 2023 Apr 20;23(2):132. doi: 10.1007/s10142-023-01059-3.
Dysregulated miRNAs have been demonstrated to be associated with the progression of colon cancer. The dysregulation of miR-3133 was observed in colon cancer, but its specific function was unclear. The functional role of miR-3133 in colon cancer was investigated in this study. A total of 113 colon cancer patients were included. miR-3133 expression was evaluated by PCR. The biological effects of miR-3133 in colon cancer cells were assessed with the help of the transwell and CCK8 assay. The prognostic value of miR-3133 was estimated by a series of statistical analyses. In mechanism, the interaction between miR-3133 and RUFY3 was evaluated by luciferase reporter. The significant downregulation of miR-3133 was observed in colon cancer, which showed a significant association with the advanced TNM stage and bad survival of patients. miR-3133 and TNM stage were identified as independent prognostic indicators of colon cancer. In vitro, the overexpression of miR-3133 exerted a dramatically inhibitory effect on cellular processes of colon cancer, which were enhanced by miR-3133 knockdown. Additionally, miR-3133 could negatively regulate the luciferase activity and expression of RUFY3, which was speculated as the underlying mechanism mediating the regulatory effect of miR-3133. miR-3133 functioned as a prognostic biomarker indicating the progression and prognosis of colon cancer, and it also served as a tumor suppressor via negatively regulating RUFY3, which provides a potential therapeutic target for colon cancer.
失调的 miRNA 已被证明与结肠癌的进展有关。在结肠癌中观察到 miR-3133 的失调，但其具体功能尚不清楚。本研究旨在探讨 miR-3133 在结肠癌中的功能作用。共纳入 113 例结肠癌患者。通过 PCR 评估 miR-3133 的表达。借助 Transwell 和 CCK8 测定评估 miR-3133 在结肠癌细胞中的生物学效应。通过一系列统计学分析估计 miR-3133 的预后价值。在机制方面，通过荧光素酶报告评估 miR-3133 与 RUFY3 的相互作用。miR-3133 在结肠癌中显著下调，与晚期 TNM 分期和患者不良生存显著相关。miR-3133 和 TNM 分期被确定为结肠癌的独立预后指标。在体外，miR-3133 的过表达对结肠癌的细胞过程产生了显著的抑制作用，而 miR-3133 的敲低则增强了这种作用。此外，miR-3133 可以负调控 RUFY3 的荧光素酶活性和表达，这被推测是介导 miR-3133 调节作用的潜在机制。miR-3133 作为一个预后生物标志物，指示结肠癌的进展和预后，通过负调控 RUFY3 发挥肿瘤抑制作用，为结肠癌提供了一个潜在的治疗靶点。
